help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siu-Caldera, M. L.
Right arrow Articles by Reddy, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siu-Caldera, M. L.
Right arrow Articles by Reddy, G. S.

Endocrinology, Vol 136, 4195-4203, Copyright © 1995 by Endocrine Society


ARTICLES

Human osteoblasts in culture metabolize both 1 alpha, 25- dihydroxyvitamin D3 and its precursor 25-hydroxyvitamin D3 into their respective lactones

ML Siu-Caldera, L Zou, MG Ehrlich, ER Schwartz, S Ishizuka and GS Reddy
Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence 02905, USA.

1 alpha, 25-Dihydroxyvitamin D3 [1 alpha, 25-(OH)2D3], the hormonal form of vitamin D3, is further metabolized in the kidney and intestine through the carbon 24 (C-24) oxidation pathway initiated by C-24 hydroxylation, and the carbon 23 (C-23) oxidation pathway initiated by C-23 hydroxylation. The C-24 oxidation pathway leading to the formation of calcitroic acid has been previously reported to be present in bone cells, but the C-23 oxidation pathway leading to the formation of 1 alpha, 25-(OH)2D3-26,23-lactone has not been described in bone cells, even though 1 alpha, 25-(OH)2D3-26,23-lactone is noted to have a significant effect on bone formation. Therefore, in the present study, we investigated the production of 1 alpha, 25-(OH)2D3-26,23-lactone in normal human osteoblasts, and our studies revealed that human osteoblasts possess the activity of both 24- and 23-hydroxylases constitutively. Thus, 1 alpha, 24(R),25-(OH)3D3, 1 alpha, 25-(OH)2-24- oxo-D3, 1 alpha, 23(S), 25-(OH)3-24-oxo-D3, 1 alpha, 23-(OH)2- 24,25,26,27-tetranor D3, and calcitroic acid formed through the C-24 oxidation pathway and 1 alpha, 23(S),25-(OH)3D3 and 1 alpha, 25-(OH)2D3- 26,23-lactone formed through the C-23 oxidation pathway were detected under basal conditions. Also, the synthesis of these metabolites was increased significantly when the cells were treated with 1 alpha, 25- (OH)2D3 (50 nM) for 24 h before incubation with the tracer. As 25- hydroxyvitamin D3 (25OHD3) follows similar side-chain modifications as 1 alpha, 25-(OH)2D3, the metabolism of 25OHD3 in normal human osteoblasts was studied under basal conditions. We found that 25OHD3 was also metabolized through both C-24 and C-23 oxidation pathways, resulting in significant synthesis of 24(R),25-(OH)2D3 along with 25OH- 24-oxo-D3, 23(S),25-(OH)2-24-oxo-D3, 23(S),25-(OH)2D3, and 25OHD3-26,23- lactone. Under the same experimental conditions, we looked for 1 alpha, 25-(OH)2D3 synthesis, as earlier studies have shown production of 1 alpha, 25-(OH)2D3 in human bone cells. During a time-course study ranging from 1-24 h, we found that by 2 h, the 24(R), 25-(OH)2D3 concentration rose and accumulated considerably during the following 24 h, but 1 alpha, 25-(OH)2D3 did not accumulate at any time. However, other 1-hydroxylated metabolites, 1 alpha, 23(S),25-(OH)3D3, 1 alpha, 23(S),25-(OH)3-24-oxo-D3, as well as 1 alpha, 25-(OH)2D3-26,23-lactone were detected.(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
EndocrinologyHome page
S. Masuda, V. Byford, A. Arabian, Y. Sakai, M. B. Demay, R. St-Arnaud, and G. Jones
Altered Pharmacokinetics of 1{alpha},25-Dihydroxyvitamin D3 and 25-Hydroxyvitamin D3 in the Blood and Tissues of the 25-Hydroxyvitamin D-24-Hydroxylase (Cyp24a1) Null Mouse
Endocrinology, February 1, 2005; 146(2): 825 - 834.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Kamao, S. Tatematsu, S. Hatakeyama, T. Sakaki, N. Sawada, K. Inouye, K. Ozono, N. Kubodera, G. S. Reddy, and T. Okano
C-3 Epimerization of Vitamin D3 Metabolites and Further Metabolism of C-3 Epimers: 25-HYDROXYVITAMIN D3 IS METABOLIZED TO 3-EPI-25-HYDROXYVITAMIN D3 AND SUBSEQUENTLY METABOLIZED THROUGH C-1{alpha} OR C-24 HYDROXYLATION
J. Biol. Chem., April 16, 2004; 279(16): 15897 - 15907.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
W. Yang, P. A. Friedman, R. Kumar, J. L. Omdahl, B. K. May, M.-L. Siu-Caldera, G. S. Reddy, and S. Christakos
Expression of 25(OH)D3 24-hydroxylase in distal nephron: coordinate regulation by 1,25(OH)2D3 and cAMP or PTH
Am J Physiol Endocrinol Metab, April 1, 1999; 276(4): E793 - E805.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Miyamoto, T. Shinki, K. Yamamoto, Y. Ohyama, H. Iwasaki, R. Hosotani, T. Kasama, H. Takayama, S. Yamada, and T. Suda
1alpha ,25-Dihydroxyvitamin D3-24-Hydroxylase (CYP24) Hydroxylates the Carbon at the End of the Side Chain (C-26) of the C-24-fluorinated Analog of 1alpha ,25-Dihydroxyvitamin D3
J. Biol. Chem., May 30, 1997; 272(22): 14115 - 14119.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society